PhaseBio to Present at Stifel 2019 Healthcare Conference
November 15 2019 - 8:00AM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiopulmonary diseases,
today announced that Chief Executive Officer Jonathan P. Mow will
present a company overview at the Stifel 2019 Healthcare Conference
on Tuesday, November 19, at 10:20 a.m. EST at the Lotte New York
Palace Hotel in New York, NY.
The event will be available via live webcast
from the “Events and Presentations” page of the “Investors” section
of the company’s website at www.phasebio.com. The webcast replay
will be available for 90 days after the conclusion of the live
presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies to treat cardiopulmonary
diseases. The company’s lead development candidate is PB2452, a
novel reversal agent for the antiplatelet therapy ticagrelor.
PhaseBio is also leveraging its proprietary elastin-like
polypeptide (“ELP”) technology platform to develop therapies with
the potential for less-frequent dosing and improved
pharmacokinetics. PhaseBio’s second product candidate PB1046, which
is based on ELP, is a once-weekly vasoactive intestinal peptide
receptor agonist for the treatment of pulmonary arterial
hypertension.
PhaseBio is located in Malvern, PA and San
Diego, CA. For more information, please
visit www.phasebio.com.
Investor Contact:John
SharpPhaseBio Pharmaceuticals, Inc. Chief Financial Officer(610)
981-6506john.sharp@phasebio.com
Media Contact:Gina Cestari6
Degrees(917) 797-7904gcestari@6degreespr.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Aug 2024 to Sep 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Sep 2023 to Sep 2024